Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount
Another In Works From Hetero
Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy.
